DekaBank Deutsche Girozentrale grew its position in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 216.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 95,000 shares of the company's stock after acquiring an additional 65,000 shares during the period. DekaBank Deutsche Girozentrale owned about 0.13% of Kura Oncology worth $1,343,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Legal & General Group Plc lifted its position in Kura Oncology by 4.0% in the 4th quarter. Legal & General Group Plc now owns 22,373 shares of the company's stock valued at $278,000 after acquiring an additional 857 shares in the last quarter. Guggenheim Capital LLC lifted its holdings in shares of Kura Oncology by 3.8% during the 1st quarter. Guggenheim Capital LLC now owns 24,671 shares of the company's stock valued at $397,000 after buying an additional 914 shares during the period. MetLife Investment Management LLC lifted its holdings in shares of Kura Oncology by 2.7% during the 4th quarter. MetLife Investment Management LLC now owns 35,896 shares of the company's stock valued at $445,000 after buying an additional 946 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Kura Oncology by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,760 shares of the company's stock valued at $291,000 after buying an additional 975 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Kura Oncology by 4.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 26,871 shares of the company's stock valued at $245,000 after buying an additional 1,115 shares during the period.
Kura Oncology Price Performance
Shares of Kura Oncology stock traded down $0.47 during trading on Monday, reaching $19.01. 751,803 shares of the stock traded hands, compared to its average volume of 1,356,508. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -9.16 and a beta of 0.85. The business has a fifty day simple moving average of $21.01 and a two-hundred day simple moving average of $14.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.26 and a quick ratio of 12.26. Kura Oncology, Inc. has a 52-week low of $7.41 and a 52-week high of $24.17.
Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.55) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.01. During the same period in the previous year, the business posted ($0.49) EPS. Sell-side analysts expect that Kura Oncology, Inc. will post -2.35 EPS for the current year.
Insider Activity
In related news, CEO Troy Edward Wilson sold 91,052 shares of the stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $20.23, for a total value of $1,841,981.96. Following the completion of the transaction, the chief executive officer now owns 559 shares of the company's stock, valued at approximately $11,308.57. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Troy Edward Wilson sold 91,052 shares of the stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $20.23, for a total value of $1,841,981.96. Following the completion of the transaction, the chief executive officer now owns 559 shares of the company's stock, valued at approximately $11,308.57. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Thomas James Doyle sold 2,318 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $17.80, for a total transaction of $41,260.40. Following the completion of the transaction, the senior vice president now directly owns 48,093 shares of the company's stock, valued at approximately $856,055.40. The disclosure for this sale can be found here. Insiders sold a total of 96,919 shares of company stock worth $1,946,415 over the last 90 days. Corporate insiders own 5.40% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the company. StockNews.com raised Kura Oncology from a "sell" rating to a "hold" rating in a report on Wednesday, April 3rd. HC Wainwright restated a "buy" rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Wednesday, March 6th. Wedbush restated an "outperform" rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Wednesday, February 28th. JMP Securities upped their price objective on Kura Oncology from $22.00 to $32.00 and gave the stock a "market outperform" rating in a research note on Wednesday, January 31st. Finally, Mizuho began coverage on Kura Oncology in a research note on Friday, December 22nd. They issued a "buy" rating and a $26.00 price target for the company. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $28.28.
Get Our Latest Stock Report on KURA
About Kura Oncology
(
Free Report)
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Featured Articles
Before you consider Kura Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kura Oncology wasn't on the list.
While Kura Oncology currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
